网站地图 联系我们搜索内部网English | 中国科学院
首页 所况简介 机构设置 科研队伍 科学研究平台 院地合作 党群园地 国际交流 博士后 研究生教育 信息公开
科研进展
成果报道
最新重要论文(影响因子PNAS及以上)
发表论文数据库
所级学术报告
科学成果
发表论文
专著
专利
获奖
专题
所史丛书
所庆专辑
建所50周年画册
现在位置:首页 > 科研进展 > 最新重要论文(影响因子PNAS及以上)
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control,Nature Comm, 28 Aug 2019
2019-08-28 | 【     】【打印】【关闭

Nature Communications28 August, 2019,DOI:https://doi.org/10.1038/s41467-019-11782-w

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu & Hua Peng

Abstract

While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity, and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely used for cancer therapy. In this study, we construct a recombinant IL-2 immunocytokine comprising a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 binding. The Ab-sumIL2 significantly enhances antitumor activity through tumor targeting and specific binding to cytotoxic T lymphocytes (CTLs). We also observe that pre-existing CTLs within the tumor are sufficient and essential for sumIL-2 therapy. This next-generation IL-2 can also overcome targeted therapy-associated resistance. In addition, preoperative sumIL-2 treatment extends survival much longer than standard adjuvant therapy. Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade through concurrent immunotherapies. Therefore, this next-generation IL-2 reduces toxicity while increasing TILs that potentiate combined cancer therapies.

文章链接:https://www.nature.com/articles/s41467-019-11782-w

 

 

评 论
          
版权所有:中国科学院生物物理研究所     京ICP备05002792号 京公网安备 110402500011 号
地址:北京市朝阳区大屯路15号(100101) 电话:010-64889872
意见反馈联系人:侯文茹 电子邮件:houwenru@ibp.ac.cn